Not overly outstanding growth, but far from abysmal as well.
Sadly, receipts are below my expectations, but considering they're currently expanding into new territories with Striate+ and the current lacklustre dental market slowly returning to some semblance of normalcy, I can only see sales increasing from here.
Tack on more incoming regulatory approvals for new products, and the impending Remplir product launch in CY25, and I'm happy to keep this in the portfolio.
Buying on weakness.
Ann: Quarterly Activity Report & Appendix 4C, page-4
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.010(2.35%) |
Mkt cap ! $86.97M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 42.5¢ | 41.5¢ | $36.29K | 86.40K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 11096 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 26292 | 2 |
View Market Depth
| Last trade - 15.55pm 01/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |